CN1049430C - 磺酰胺类化合物、其制备方法及其应用 - Google Patents

磺酰胺类化合物、其制备方法及其应用 Download PDF

Info

Publication number
CN1049430C
CN1049430C CN93120171A CN93120171A CN1049430C CN 1049430 C CN1049430 C CN 1049430C CN 93120171 A CN93120171 A CN 93120171A CN 93120171 A CN93120171 A CN 93120171A CN 1049430 C CN1049430 C CN 1049430C
Authority
CN
China
Prior art keywords
chloro
pyrimidine
methoxyl group
benzsulfamide
tertiary butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN93120171A
Other languages
English (en)
Chinese (zh)
Other versions
CN1095375A (zh
Inventor
V·布卢
K·布力
Ｊ·－Ｍ·卡萨尔
M·克罗策尔
G·赫思
Ｂ·－Ｍ·勒弗勒
M·米勒
W·乃哈特
H·拉木兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1095375A publication Critical patent/CN1095375A/zh
Application granted granted Critical
Publication of CN1049430C publication Critical patent/CN1049430C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Bipolar Transistors (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Heat Treatment Of Articles (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN93120171A 1992-12-10 1993-12-09 磺酰胺类化合物、其制备方法及其应用 Expired - Fee Related CN1049430C (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CH3777/1992 1992-12-10
CH377792 1992-12-10
CH3777/92 1992-12-10
CH379992 1992-12-11
CH3799/92 1992-12-11
CH3799/1992 1992-12-11
CH311493 1993-10-14
CH3114/1993 1993-10-14
CH3114/93 1993-10-14

Publications (2)

Publication Number Publication Date
CN1095375A CN1095375A (zh) 1994-11-23
CN1049430C true CN1049430C (zh) 2000-02-16

Family

ID=27174140

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93120171A Expired - Fee Related CN1049430C (zh) 1992-12-10 1993-12-09 磺酰胺类化合物、其制备方法及其应用

Country Status (19)

Country Link
US (1) US5420129A (enExample)
EP (1) EP0601386B1 (enExample)
JP (1) JPH0826006B2 (enExample)
KR (1) KR100300503B1 (enExample)
CN (1) CN1049430C (enExample)
AT (1) ATE232204T1 (enExample)
AU (1) AU669019B2 (enExample)
CA (1) CA2110944A1 (enExample)
CZ (1) CZ288030B6 (enExample)
DE (1) DE59310329D1 (enExample)
DK (1) DK0601386T3 (enExample)
ES (1) ES2190430T3 (enExample)
FI (1) FI112217B (enExample)
HU (1) HUT65689A (enExample)
IL (1) IL107884A (enExample)
NO (1) NO306344B1 (enExample)
NZ (1) NZ250347A (enExample)
PH (1) PH30118A (enExample)
TW (1) TW287160B (enExample)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
US5767310A (en) * 1993-03-19 1998-06-16 Merck & Co., Inc. Phenoxyphenylacetic acid derivatives
US6030991A (en) * 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
TW394761B (en) * 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
US5686478A (en) * 1993-07-20 1997-11-11 Merck & Co. Inc. Endothelin antagonists
IL111959A (en) * 1993-12-17 2000-07-16 Tanabe Seiyaku Co N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) * 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5559135A (en) * 1994-09-14 1996-09-24 Merck & Co., Inc. Endothelin antagonists bearing pyridyl amides
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides
CA2162630C (en) * 1994-11-25 2007-05-01 Volker Breu Sulfonamides
PL188801B1 (pl) * 1994-12-20 2005-04-29 Fhoffmann La Roche Ag Nowe sulfonamidy i zawierające je preparaty farmaceutyczne
AU695255B2 (en) * 1994-12-20 1998-08-13 F. Hoffmann-La Roche Ag Aryl- and hetaryl-sulfonamide derivatives, their preparation and their use as endothelin antagonists
TW313568B (enExample) * 1994-12-20 1997-08-21 Hoffmann La Roche
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5573762A (en) 1995-04-24 1996-11-12 Genentech, Inc. Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy
US5739333A (en) * 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
UA58494C2 (uk) 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9512697D0 (en) * 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
KR100453097B1 (ko) * 1995-09-06 2004-12-31 코와 가부시키가이샤 피리미딘유도체
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
CZ260596A3 (en) * 1995-10-12 1997-12-17 Hoffmann La Roche Sulfonamide derivative, process of its preparation and pharmaceutical composition containing thereof
WO1997022595A1 (en) * 1995-12-20 1997-06-26 Yamanouchi Pharmaceutical Co., Ltd. Arylethenesulfonamide derivatives and drug composition containing the same
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
WO1997029747A1 (en) 1996-02-20 1997-08-21 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US5958905A (en) 1996-03-26 1999-09-28 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
EP0956041A1 (en) * 1996-09-16 1999-11-17 Dalhousie University Use of igf-i for the treatment of polycystic kidney disease and related indications
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
WO1998033781A1 (en) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
US5783705A (en) * 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
ATE292129T1 (de) 1997-04-28 2005-04-15 Encysive Pharmaceuticals Inc Sulfonamide für die behandlung von störungen durch endothelin vermittelt
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
JP2002540088A (ja) 1999-03-19 2002-11-26 ブリストル−マイヤーズ スクイブ カンパニー ビフェニルイソキサゾール・スルホンアミド化合物の製造法
DK1254121T3 (da) * 2000-01-25 2006-06-12 Hoffmann La Roche Fremstilling af sulfonamider
WO2001081335A1 (en) * 2000-04-20 2001-11-01 Actelion Pharmaceuticals Ltd Pyrimidine-sulfonamides having endothelin-antagonist activity
AU2001265871A1 (en) * 2000-04-25 2001-11-07 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
MY140724A (en) * 2000-07-21 2010-01-15 Actelion Pharmaceuticals Ltd Novel arylethene-sulfonamides
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
UA77454C2 (en) 2001-10-26 2006-12-15 N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
EP1441734B1 (en) 2001-10-26 2007-02-28 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
NZ536504A (en) * 2002-05-24 2008-04-30 Millennium Pharm Inc CCR9 inhibitors and methods of use thereof
SG176311A1 (en) * 2002-07-29 2011-12-29 Rigel Pharmaceuticals Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
DE102004027119A1 (de) 2003-06-06 2004-12-30 Schott Ag UV-Strahlung absorbierendes Glas mit geringer Absorption im sichtbaren Bereich, ein Verfahren zu seiner Herstellung sowie dessen Verwendung
HRP20130602T1 (en) * 2003-07-30 2013-07-31 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
BRPI0512705A (pt) * 2004-06-28 2008-04-01 Hoffmann La Roche composto, processo de preparação deste e método para o tratamento e profilaxia de diabetes, obesidade, distúrbios alimentares, dilipidemia, hipertensão e diabetes do tipo ii
KR100847203B1 (ko) * 2004-06-28 2008-07-17 에프. 호프만-라 로슈 아게 피리미딘 유도체
ES2380550T3 (es) * 2004-11-24 2012-05-16 Rigel Pharmaceuticals, Inc. Compuestos de espiro-2,4-pirimidindiamina y sus usos
WO2007027238A2 (en) * 2005-05-03 2007-03-08 Rigel Pharmaceuticals, Inc. Jak kinase inhibitors and their uses
CN101404981A (zh) * 2006-03-13 2009-04-08 恩希赛弗制药公司 治疗舒张性心力衰竭的方法和组合物
KR20080102200A (ko) * 2006-03-13 2008-11-24 엔싸이시브 파마슈티칼즈 인코퍼레이티드 시탁센탄 나트륨의 제제
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
EP2240470A4 (en) * 2008-01-10 2012-05-23 Msn Lab Ltd IMPROVED AND NEW PROCESS FOR THE PREPARATION OF BOSENTAN
US9315491B2 (en) 2009-12-28 2016-04-19 Development Center For Biotechnology Pyrimidine compounds as mTOR and PI3K inhibitors
RU2538200C2 (ru) * 2009-12-28 2015-01-10 Дивелэпмэнт Сентэ Фо Байэутекнолэджи ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), СПОСОБ ИХ ПОЛУЧЕНИЯ, КОМПОЗИЦИЯ ИХ СОДЕРЖАЩАЯ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С КИНАЗОЙ mTOR ИЛИ КИНАЗОЙ PI3K
WO2016004358A1 (en) 2014-07-03 2016-01-07 Afferent Pharmaceuticals, Inc. Methods and compositions for treating diseases and conditions
EP4149929B1 (en) 2020-05-12 2026-01-28 Bayer Aktiengesellschaft Triazine and pyrimidine (thio)amides as fungicidal compounds
JP2023528891A (ja) 2020-06-04 2023-07-06 バイエル、アクチエンゲゼルシャフト 新規殺真菌剤としてのヘテロシクリルピリミジンおよびトリアジン
CN118201908A (zh) * 2021-11-08 2024-06-14 正大天晴药业集团股份有限公司 氮杂联苯类化合物及其应用
CN118667088A (zh) * 2024-05-30 2024-09-20 中国人民解放军北部战区总医院 二茂铁基硫代二氢嘧啶酮结构的聚合物及制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0510526A1 (de) * 1991-04-25 1992-10-28 F.Hoffmann-La Roche & Co. Aktiengesellschaft Verwendung von Sulfonamiden als Heilmittel und neue Sulfonamide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0510526A1 (de) * 1991-04-25 1992-10-28 F.Hoffmann-La Roche & Co. Aktiengesellschaft Verwendung von Sulfonamiden als Heilmittel und neue Sulfonamide

Also Published As

Publication number Publication date
NO934502D0 (no) 1993-12-09
US5420129A (en) 1995-05-30
CN1095375A (zh) 1994-11-23
KR100300503B1 (ko) 2001-11-22
NO934502L (no) 1994-06-13
CZ288030B6 (cs) 2001-04-11
PH30118A (en) 1996-12-27
HUT65689A (en) 1994-07-28
FI935555A0 (fi) 1993-12-10
CA2110944A1 (en) 1994-06-11
EP0601386B1 (de) 2003-02-05
CZ268493A3 (en) 1994-06-15
DE59310329D1 (de) 2003-03-13
TW287160B (enExample) 1996-10-01
IL107884A (en) 1998-03-10
JPH06211810A (ja) 1994-08-02
DK0601386T3 (da) 2003-05-26
IL107884A0 (en) 1994-04-12
KR940014347A (ko) 1994-07-18
ES2190430T3 (es) 2003-08-01
FI935555L (fi) 1994-06-11
NZ250347A (en) 1995-12-21
AU5218993A (en) 1994-06-23
ATE232204T1 (de) 2003-02-15
JPH0826006B2 (ja) 1996-03-13
HU9303458D0 (en) 1994-04-28
NO306344B1 (no) 1999-10-25
FI112217B (fi) 2003-11-14
EP0601386A1 (de) 1994-06-15
AU669019B2 (en) 1996-05-23

Similar Documents

Publication Publication Date Title
CN1049430C (zh) 磺酰胺类化合物、其制备方法及其应用
CN1129597C (zh) 杂环化合物和以其为有效成分的抗肿瘤剂
CN1050839C (zh) 磺酰氨基嘧啶类化合物，含有它们的药物组合物及其制备方法与用途
CN1171885C (zh) 苯并咪唑衍生物晶体及其制备
CN100339080C (zh) 抗病毒大环化合物
CN1045776C (zh) 吡啶环取代的噻唑烷和噁唑烷以及它们作为降血糖药的用途
CN1064272A (zh) 吡喃基氰基胍衍生物
CN1872850A (zh) N－苯基－2－嘧啶胺衍生物
CN1060172C (zh) 取代的联苯磺酰胺类内皮素拮抗剂
CN1190424C (zh) 含喹啉的α－酮酰胺半胱氨酸和丝氨酸蛋白酶抑制剂
CN1561340A (zh) 新的1,2,4－三唑类化合物
CN1192739A (zh) N－杂芳基吡啶磺酰胺衍生物及其作为内皮素拮抗剂的用途
CN1636992A (zh) 喹唑啉类化合物的制备方法
CN1524079A (zh) 新颖的磺酰胺类化合物及其作为内皮素受体拮抗剂的应用
CN1296488A (zh) 双环异羟肟酸类衍生物
CN1324360A (zh) 双环氮杂环
CN1694708A (zh) TGFβ的抑制剂
CN1144802A (zh) 哒嗪酮衍生物及其制备方法
CN1070488C (zh) 杀灭螺旋杆菌用的取代芳烷基硫代烷基硫代吡啶
CN1051766C (zh) 血管紧张素ⅱ拮抗剂咪唑衍生物，它们的制备及其治疗用途
CN1305472A (zh) 新的2,5－吡啶二羧酸衍生物
CN1662510A (zh) 5－(1,3－噁唑－2－基)苯甲酸衍生物的制备方法
CN1263746C (zh) 哒嗪酮衍生物
CN1061350C (zh) 2,7－取代的八氢－吡咯并[1,2－a]吡嗪衍生物
CN1441788A (zh) 新颖的芳乙烯磺胺类化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee